Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2045-2322

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models ; volume:9 ; number:1 ; day:12 ; month:2 ; year:2019 ; pages:1-12 ; date:12.2019
Scientific reports ; 9, Heft 1 (12.2.2019), 1-12, 12.2019

Classification: Naturwissenschaften

Creator: Wang, Zebin
Sun, Kaiming
Xiao, Yonghong
Feng, Bin
Mikule, Keith
Ma, XiaoYan
Feng, Ningping
Vellano, Christopher P.
Federico, Lorenzo
Marszalek, Joseph R.
Mills, Gordon B.
Hanke, Jeffrey
Ramaswamy, Sridhar
Wang, Jing

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41598-019-38534-6

URN: urn:nbn:de:101:1-2019031122472523324572

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:58 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Wang, Zebin
Sun, Kaiming
Xiao, Yonghong
Feng, Bin
Mikule, Keith
Ma, XiaoYan
Feng, Ningping
Vellano, Christopher P.
Federico, Lorenzo
Marszalek, Joseph R.
Mills, Gordon B.
Hanke, Jeffrey
Ramaswamy, Sridhar
Wang, Jing
SpringerLink (Online service)

Other Objects (12)

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer

Interruption of post-Golgi STING trafficking activates tonic interferon signaling

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma

Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma

Type I Interferon Potentiates IgA Immunity to Respiratory Syncytial Virus Infection During Infancy

Interferon‐mediated repression of miR ‐324‐5p potentiates necroptosis to facilitate antiviral defense

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer

Interruption of post-Golgi STING trafficking activates tonic interferon signaling

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma

Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma

Type I Interferon Potentiates IgA Immunity to Respiratory Syncytial Virus Infection During Infancy

Interferon‐mediated repression of miR ‐324‐5p potentiates necroptosis to facilitate antiviral defense

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer

Interruption of post-Golgi STING trafficking activates tonic interferon signaling

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma

Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma

Type I Interferon Potentiates IgA Immunity to Respiratory Syncytial Virus Infection During Infancy

Interferon‐mediated repression of miR ‐324‐5p potentiates necroptosis to facilitate antiviral defense

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer

Interruption of post-Golgi STING trafficking activates tonic interferon signaling

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma

Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma

Type I Interferon Potentiates IgA Immunity to Respiratory Syncytial Virus Infection During Infancy

Interferon‐mediated repression of miR ‐324‐5p potentiates necroptosis to facilitate antiviral defense

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer

Interruption of post-Golgi STING trafficking activates tonic interferon signaling

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma

Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma

Type I Interferon Potentiates IgA Immunity to Respiratory Syncytial Virus Infection During Infancy

Interferon‐mediated repression of miR ‐324‐5p potentiates necroptosis to facilitate antiviral defense

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer

Interruption of post-Golgi STING trafficking activates tonic interferon signaling

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma

Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma

Type I Interferon Potentiates IgA Immunity to Respiratory Syncytial Virus Infection During Infancy

Interferon‐mediated repression of miR ‐324‐5p potentiates necroptosis to facilitate antiviral defense

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy

Related objects

Reset password